Zimmer Biomet Holdings (ZBH): Sales Miss Was Disappointing But Now Its In The Stock - Leerink

November 1, 2016 7:05 AM EDT
Get Alerts ZBH Hot Sheet
Price: $115.47 +0.02%

Rating Summary:
    24 Buy, 13 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade ZBH Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners analyst, Richard Newitter, reiterated his Outperform rating on shares of Zimmer Biomet (NYSE: ZBH) but cut the price target to $136 from $150.

The analyst thinks ZBH’s 3Q sales miss was disappointing but considering the 14% pullback, with ZBH back at a ~6x P/E discount to the large cap MedTech avg., the valuation appears to be disconnected from the company’s double digit EPS growth prospects and longer-term mid single digit top-line potential.

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $105.40 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Add Your Comment